Osborne Clarke advises the investors of the $50M Series B financing round of BioClin Therapeutics

Written on 16 May 2018

International legal practice Osborne Clarke represented new investors INKEF Capital and Sectoral Asset Management as well as existing investors Sofinnova Ventures and Ysios Capital in respect of the USD 50 million Series B financing round of BioClin Therapeutics.

Other investors include HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP). BioClin Therapeutics is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The additional funding will allow the company to move forward with the only targeted biologic specific for FGFR3 in clinical development for bladder cancer.

The Osborne Clarke in Amsterdam team consisted of Herke van Hulst and Geoffrey Beurskens.

Osborne Clarke’s market leading venture capital team is considered a go-to practice. The team across Europe, Asia and the US combine extensive market knowledge and deep sector expertise to support companies throughout all stages of their developments, from start-up to later stage and growth capital funding, strategic M&A and exits, acting for founders, companies, and financial and strategic investors. The team has particular expertise in the tech, media and comms, financial services and life sciences sectors.

Connect with one of our experts

Herke van Hulst

Partner, Advocaat, The Netherlands

T +31 20 702 8672

Email Herke

Full Biog

Geoffrey Beurskens

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8682

Email Geoffrey

Full Biog